Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.

The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein-ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.

[1]  I. Belfer,et al.  An SCN9A variant, known to cause pain, is now found to cause itch , 2014, Pain.

[2]  Richard D. LeDuc,et al.  Quantitative Proteomics Reveals Protein–Protein Interactions with Fibroblast Growth Factor 12 as a Component of the Voltage-Gated Sodium Channel 1.2 (Nav1.2) Macromolecular Complex in Mammalian Brain , 2015, Molecular & Cellular Proteomics.

[3]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[4]  S. Waxman,et al.  Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents. , 2014, Handbook of experimental pharmacology.

[5]  M. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001 .

[6]  Irina Vetter,et al.  No gain, no pain: NaV1.7 as an analgesic target. , 2014, ACS chemical neuroscience.

[7]  C. Cohen,et al.  Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. , 2014, Pharmaceutical patent analyst.

[8]  P. A. Bradley,et al.  Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7. , 2017, Journal of medicinal chemistry.

[9]  T. Kan,et al.  Ns strategies: a highly versatile synthetic method for amines. , 2004, Chemical communications.

[10]  R. L. Kirby,et al.  SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. , 2005, The Journal of investigative dermatology.

[11]  John N. Wood,et al.  Neurological perspectives on voltage-gated sodium channels , 2012, Brain : a journal of neurology.

[12]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[13]  Jun Li,et al.  Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist , 2015, Science.

[14]  Sulayman D. Dib-Hajj,et al.  Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release , 2016, PloS one.

[15]  Alex Phipps,et al.  Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels , 2016, Clinical Pharmacokinetics.

[16]  J. Boorman,et al.  Voltage-gated sodium channel blockers; target validation and therapeutic potential. , 2005, Current topics in medicinal chemistry.

[17]  M. D. de Groot,et al.  Subtype‐selective targeting of voltage‐gated sodium channels , 2009, British journal of pharmacology.

[18]  Paul Morgan,et al.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.

[19]  Dafydd R Owen,et al.  Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.

[20]  P. Myler,et al.  The Putative Leishmania Telomerase RNA (LeishTER) Undergoes Trans-Splicing and Contains a Conserved Template Sequence , 2014, PloS one.

[21]  Shifeng Liu,et al.  Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. , 2016, ACS medicinal chemistry letters.

[22]  Dong Liu,et al.  Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. , 2016, Journal of medicinal chemistry.

[23]  M. D. de Groot,et al.  Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels , 2013, Proceedings of the National Academy of Sciences.

[24]  Sharan K Bagal,et al.  Recent progress in sodium channel modulators for pain. , 2014, Bioorganic & medicinal chemistry letters.

[25]  N. Damann,et al.  Advances in Targeting Voltage‐Gated Sodium Channels with Small Molecules , 2012, ChemMedChem.

[26]  S. England.  Voltage-gated sodium channels: the search for subtype-selective analgesics , 2008, Expert opinion on investigational drugs.

[27]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[28]  Manuel de Lera Ruiz,et al.  Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. , 2015, Journal of medicinal chemistry.

[29]  A. Malmberg,et al.  Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to Pain , 2014, PloS one.

[30]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[31]  S. Dib-Hajj,et al.  The NaV1.7 sodium channel: from molecule to man , 2012, Nature Reviews Neuroscience.

[32]  S. Buchwald,et al.  General catalysts for the Suzuki-Miyaura and Sonogashira coupling reactions of aryl chlorides and for the coupling of challenging substrate combinations in water. , 2005, Angewandte Chemie.

[33]  S. England,et al.  Isoform-selective voltage-gated Na(+) channel modulators as next-generation analgesics. , 2010, Future medicinal chemistry.

[34]  Mark E Bunnage,et al.  Know your target, know your molecule. , 2015, Nature chemical biology.

[35]  Ronald T Raines,et al.  Bright ideas for chemical biology. , 2008, ACS chemical biology.

[36]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[37]  R. Fremeau,et al.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. , 2016, ACS medicinal chemistry letters.

[38]  S. Waxman,et al.  Paroxysmal itch caused by gain-of-function Nav1.7 mutation , 2014, PAIN®.

[39]  R. M. Owen,et al.  Ion channels as therapeutic targets: a drug discovery perspective. , 2013, Journal of medicinal chemistry.